Clinical trial · no report yet · Phase 2
NCT04172675
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
- NCT04172675 ↗
- Completed
- Janssen Research & Development, LLC
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- Erdafitinib; Investigator Choice (Gemcitabine); Investigator Choice (Mitomycin C)
- Arms
- Cohort 1: Erdafitinib · Experimental
- Cohort 1: Investigators Choice · Active comparator
- Cohort 2 · Experimental
- Cohort 3 · Experimental
- Enrollment
- 107
- Primary outcomes
- Cohort 1: Recurrence-Free Survival (RFS)
- Sponsor
- Janssen Research & Development, LLC
- Start
- Feb 28, 2020
- Primary completion
- Jul 12, 2024
- Results posted
- Yes
- Registry record
- NCT04172675 · updated Feb 24, 2026
Publications
linked from the registry- Han MA, Maisch P, Jung JH, Hwang JE, Narayan V, Cleves A, Hwang EC, Dahm P. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev. 2021 Jun 14;6(6):CD009294. doi: 10.1002/14651858.CD009294.pub3. PubMed 34125951